6jp8 › Citations

Molecular Basis for Ligand Modulation of a Mammalian Voltage-Gated Ca2+ Channel.

Zhao Y, Huang G, Wu J, Wu Q, Gao S, Yan Z, Lei J, Yan N
Cell 177 1495-1506.e12 (2019)
Related entries: 6jp5, 6jpa, 6jpb

Cited: 98 times
EuropePMC logo PMID: 31150622

Abstract

The L-type voltage-gated Ca2+ (Cav) channels are modulated by various compounds exemplified by 1,4-dihydropyridines (DHP), benzothiazepines (BTZ), and phenylalkylamines (PAA), many of which have been used for characterizing channel properties and for treatment of hypertension and other disorders. Here, we report the cryoelectron microscopy (cryo-EM) structures of Cav1.1 in complex with archetypal antagonistic drugs, nifedipine, diltiazem, and verapamil, at resolutions of 2.9 Å, 3.0 Å, and 2.7 Å, respectively, and with a DHP agonist Bay K 8644 at 2.8 Å. Diltiazem and verapamil traverse the central cavity of the pore domain, directly blocking ion permeation. Although nifedipine and Bay K 8644 occupy the same fenestration site at the interface of repeats III and IV, the coordination details support previous functional observations that Bay K 8644 is less favored in the inactivated state. These structures elucidate the modes of action of different Cav ligands and establish a framework for structure-guided drug discovery.

Reviews - 6jp8 mentioned but not cited (3)

  1. Cryo-EM as a powerful tool for drug discovery. Van Drie JH, Tong L. Bioorg Med Chem Lett 30 127524 (2020)
  2. Neuronal α2δ proteins and brain disorders. Ablinger C, Geisler SM, Stanika RI, Klein CT, Obermair GJ. Pflugers Arch 472 845-863 (2020)
  3. Structural biology of voltage-gated calcium channels. Yao X, Gao S, Yan N. Channels (Austin) 18 2290807 (2024)

Articles - 6jp8 mentioned but not cited (6)

  1. Structural Basis of the Modulation of the Voltage-Gated Calcium Ion Channel Cav 1.1 by Dihydropyridine Compounds*. Gao S, Yan N. Angew Chem Int Ed Engl 60 3131-3137 (2021)
  2. Mechanisms of dihydropyridine agonists and antagonists in view of cryo-EM structures of calcium and sodium channels. Tikhonov DB, Zhorov BS. J Gen Physiol 155 e202313418 (2023)
  3. Structural bases of inhibitory mechanism of CaV1.2 channel inhibitors. Wei Y, Yu Z, Wang L, Li X, Li N, Bai Q, Wang Y, Li R, Meng Y, Xu H, Wang X, Dong Y, Huang Z, Zhang XC, Zhao Y. Nat Commun 15 2772 (2024)
  4. A governance of ion selectivity based on the occupancy of the "beacon" in one- and four-domain calcium and sodium channels. Spafford JD. Channels (Austin) 17 2191773 (2023)
  5. Ex Vivo and In Silico Approaches of Tracheal Relaxation through Calcium Channel Blockade of 6-Aminoflavone and Its Toxicological Studies in Murine Models. Flores-Flores A, Estrada-Soto S, Millán-Pacheco C, Bazán-Perkins B, Hernández-Pando R, Ibarra-Barajas M, Villalobos-Molina R. Biomedicines 11 1870 (2023)
  6. Toward high-resolution modeling of small molecule-ion channel interactions. Harris BJ, Nguyen PT, Zhou G, Wulff H, DiMaio F, Yarov-Yarovoy V. Front Pharmacol 15 1411428 (2024)


Reviews citing this publication (26)

  1. Developments, applications, and prospects of cryo-electron microscopy. Benjin X, Ling L. Protein Sci 29 872-882 (2020)
  2. Ligand binding at the protein-lipid interface: strategic considerations for drug design. Payandeh J, Volgraf M. Nat Rev Drug Discov 20 710-722 (2021)
  3. Voltage-Gated Ca2+-Channel α1-Subunit de novo Missense Mutations: Gain or Loss of Function - Implications for Potential Therapies. Striessnig J. Front Synaptic Neurosci 13 634760 (2021)
  4. Regulatory mechanisms of ryanodine receptor/Ca2+ release channel revealed by recent advancements in structural studies. Ogawa H, Kurebayashi N, Yamazawa T, Murayama T. J Muscle Res Cell Motil 42 291-304 (2021)
  5. Structure and function of STAC proteins: Calcium channel modulators and critical components of muscle excitation-contraction coupling. Rufenach B, Van Petegem F. J Biol Chem 297 100874 (2021)
  6. Druggability of Voltage-Gated Sodium Channels-Exploring Old and New Drug Receptor Sites. Wisedchaisri G, Gamal El-Din TM. Front Pharmacol 13 858348 (2022)
  7. Designer genetically encoded voltage-dependent calcium channel inhibitors inspired by RGK GTPases. Colecraft HM. J Physiol 598 1683-1693 (2020)
  8. Zebrafish as a Model System for the Study of Severe CaV2.1 (α1A) Channelopathies. Tyagi S, Ribera AB, Bannister RA. Front Mol Neurosci 12 329 (2019)
  9. Voltage gated sodium and calcium channels: Discovery, structure, function, and Pharmacology. Catterall WA. Channels (Austin) 17 2281714 (2023)
  10. Excitation-transcription coupling, neuronal gene expression and synaptic plasticity. Ma H, Khaled HG, Wang X, Mandelberg NJ, Cohen SM, He X, Tsien RW. Nat Rev Neurosci 24 672-692 (2023)
  11. P-Loop Channels: Experimental Structures, and Physics-Based and Neural Networks-Based Models. Tikhonov DB, Zhorov BS. Membranes (Basel) 12 229 (2022)
  12. Ionic channels in nerve membranes, 50 years on. Hille B. Prog Biophys Mol Biol 169-170 12-20 (2022)
  13. Ventricular voltage-gated ion channels: Detection, characteristics, mechanisms, and drug safety evaluation. Chen L, He Y, Wang X, Ge J, Li H. Clin Transl Med 11 e530 (2021)
  14. Cav 1.3-selective inhibitors of voltage-gated L-type Ca2+ channels: Fact or (still) fiction? Filippini L, Ortner NJ, Kaserer T, Striessnig J. Br J Pharmacol 180 1289-1303 (2023)
  15. Excitation-contraction coupling in mammalian skeletal muscle: Blending old and last-decade research. Bolaños P, Calderón JC. Front Physiol 13 989796 (2022)
  16. Simulation and Machine Learning Methods for Ion-Channel Structure Determination, Mechanistic Studies and Drug Design. Zhu Z, Deng Z, Wang Q, Wang Y, Zhang D, Xu R, Guo L, Wen H. Front Pharmacol 13 939555 (2022)
  17. Structural Insight Into Ryanodine Receptor Channelopathies. Hadiatullah H, He Z, Yuchi Z. Front Pharmacol 13 897494 (2022)
  18. Structural Mechanisms of Store-Operated and Mitochondrial Calcium Regulation: Initiation Points for Drug Discovery. Noble M, Lin QT, Sirko C, Houpt JA, Novello MJ, Stathopulos PB. Int J Mol Sci 21 E3642 (2020)
  19. Advances in CaV1.1 gating: New insights into permeation and voltage-sensing mechanisms. Bibollet H, Kramer A, Bannister RA, Hernández-Ochoa EO. Channels (Austin) 17 2167569 (2023)
  20. Electron microscopy of cardiac 3D nanodynamics: form, function, future. Kohl P, Greiner J, Rog-Zielinska EA. Nat Rev Cardiol 19 607-619 (2022)
  21. Recent advances in skeletal muscle physiology. Kaura V, Hopkins PM. BJA Educ 24 84-90 (2024)
  22. Synthesis of the 1,5-Benzothiazepane Scaffold - Established Methods and New Developments. Ronse U, Magdalenić K, Van Camp J, D'hooghe M. ChemistryOpen 12 e202200262 (2023)
  23. Design and Applications of Genetically-Encoded Voltage-Dependent Calcium Channel Inhibitors. Gavin AC, Colecraft HM. Handb Exp Pharmacol 279 139-155 (2023)
  24. Electrophysiological evaluation of the effect of peptide toxins on voltage-gated ion channels: a scoping review on theoretical and methodological aspects with focus on the Central and South American experience. Rojas-Palomino J, Gómez-Restrepo A, Salinas-Restrepo C, Segura C, Giraldo MA, Calderón JC. J Venom Anim Toxins Incl Trop Dis 30 e20230048 (2024)
  25. Structural biology and molecular pharmacology of voltage-gated ion channels. Huang J, Pan X, Yan N. Nat Rev Mol Cell Biol (2024)
  26. Structural modeling of ion channels using AlphaFold2, RoseTTAFold2, and ESMFold. Nguyen PT, Harris BJ, Mateos DL, González AH, Murray AM, Yarov-Yarovoy V. Channels (Austin) 18 2325032 (2024)

Articles citing this publication (63)

  1. Cryo-EM structures of apo and antagonist-bound human Cav3.1. Zhao Y, Huang G, Wu Q, Wu K, Li R, Lei J, Pan X, Yan N. Nature 576 492-497 (2019)
  2. Structure of human Cav2.2 channel blocked by the painkiller ziconotide. Gao S, Yao X, Yan N. Nature 596 143-147 (2021)
  3. Molecular basis for ligand activation of the human KCNQ2 channel. Li X, Zhang Q, Guo P, Fu J, Mei L, Lv D, Wang J, Lai D, Ye S, Yang H, Guo J. Cell Res 31 52-61 (2021)
  4. Connecting Calcium-Based Nanomaterials and Cancer: From Diagnosis to Therapy. Bai S, Lan Y, Fu S, Cheng H, Lu Z, Liu G. Nanomicro Lett 14 145 (2022)
  5. Structure of the human sodium leak channel NALCN. Kschonsak M, Chua HC, Noland CL, Weidling C, Clairfeuille T, Bahlke OØ, Ameen AO, Li ZR, Arthur CP, Ciferri C, Pless SA, Payandeh J. Nature 587 313-318 (2020)
  6. Letter Structural basis for pore blockade of human voltage-gated calcium channel Cav1.3 by motion sickness drug cinnarizine. Yao X, Gao S, Yan N. Cell Res 32 946-948 (2022)
  7. Amino acid sensor conserved from bacteria to humans. Gumerov VM, Andrianova EP, Matilla MA, Page KM, Monteagudo-Cascales E, Dolphin AC, Krell T, Zhulin IB. Proc Natl Acad Sci U S A 119 e2110415119 (2022)
  8. Employing NaChBac for cryo-EM analysis of toxin action on voltage-gated Na+ channels in nanodisc. Gao S, Valinsky WC, On NC, Houlihan PR, Qu Q, Liu L, Pan X, Clapham DE, Yan N. Proc Natl Acad Sci U S A 117 14187-14193 (2020)
  9. Structural Basis for Diltiazem Block of a Voltage-Gated Ca2+ Channel. Tang L, Gamal El-Din TM, Lenaeus MJ, Zheng N, Catterall WA. Mol Pharmacol 96 485-492 (2019)
  10. Structure of the human sodium leak channel NALCN in complex with FAM155A. Xie J, Ke M, Xu L, Lin S, Huang J, Zhang J, Yang F, Wu J, Yan Z. Nat Commun 11 5831 (2020)
  11. Structure, gating, and pharmacology of human CaV3.3 channel. He L, Yu Z, Geng Z, Huang Z, Zhang C, Dong Y, Gao Y, Wang Y, Chen Q, Sun L, Ma X, Huang B, Wang X, Zhao Y. Nat Commun 13 2084 (2022)
  12. The distinct role of the four voltage sensors of the skeletal CaV1.1 channel in voltage-dependent activation. Savalli N, Angelini M, Steccanella F, Wier J, Wu F, Quinonez M, DiFranco M, Neely A, Cannon SC, Olcese R. J Gen Physiol 153 e202112915 (2021)
  13. Structural determinants of voltage-gating properties in calcium channels. Fernández-Quintero ML, El Ghaleb Y, Tuluc P, Campiglio M, Liedl KR, Flucher BE. Elife 10 e64087 (2021)
  14. Structural mapping of Nav1.7 antagonists. Wu Q, Huang J, Fan X, Wang K, Jin X, Huang G, Li J, Pan X, Yan N. Nat Commun 14 3224 (2023)
  15. EMC chaperone-CaV structure reveals an ion channel assembly intermediate. Chen Z, Mondal A, Abderemane-Ali F, Jang S, Niranjan S, Montaño JL, Zaro BW, Minor DL. Nature 619 410-419 (2023)
  16. Redefining the role of Ca2+-permeable channels in photoreceptor degeneration using diltiazem. Das S, Popp V, Power M, Groeneveld K, Yan J, Melle C, Rogerson L, Achury M, Schwede F, Strasser T, Euler T, Paquet-Durand F, Nache V. Cell Death Dis 13 47 (2022)
  17. Structural basis for NaV1.7 inhibition by pore blockers. Zhang J, Shi Y, Huang Z, Li Y, Yang B, Gong J, Jiang D. Nat Struct Mol Biol 29 1208-1216 (2022)
  18. The β-cell primary cilium is an autonomous Ca2+ compartment for paracrine GABA signaling. Sanchez GM, Incedal TC, Prada J, O'Callaghan P, Dyachok O, Echeverry S, Dumral Ö, Dumral Ö, Nguyen PM, Xie B, Barg S, Kreuger J, Dandekar T, Idevall-Hagren O. J Cell Biol 222 e202108101 (2023)
  19. A Single Amino Acid Determines the Selectivity and Efficacy of Selective Negative Allosteric Modulators of CaV1.3 L-Type Calcium Channels. Cooper G, Kang S, Perez-Rosello T, Guzman JN, Galtieri D, Xie Z, Kondapalli J, Mordell J, Silverman RB, Surmeier DJ. ACS Chem Biol 15 2539-2550 (2020)
  20. Structural mechanisms for the activation of human cardiac KCNQ1 channel by electro-mechanical coupling enhancers. Ma D, Zhong L, Yan Z, Yao J, Zhang Y, Ye F, Huang Y, Lai D, Yang W, Hou P, Guo J. Proc Natl Acad Sci U S A 119 e2207067119 (2022)
  21. Structures of the R-type human Cav2.3 channel reveal conformational crosstalk of the intracellular segments. Yao X, Wang Y, Wang Z, Fan X, Wu D, Huang J, Mueller A, Gao S, Hu M, Robinson CV, Yu Y, Gao S, Yan N. Nat Commun 13 7358 (2022)
  22. The molecular evolution of function in the CFTR chloride channel. Infield DT, Strickland KM, Gaggar A, McCarty NA. J Gen Physiol 153 e202012625 (2021)
  23. CaV1.2 channelopathic mutations evoke diverse pathophysiological mechanisms. Bamgboye MA, Herold KG, Vieira DCO, Traficante MK, Rogers PJ, Ben-Johny M, Dick IE. J Gen Physiol 154 e202213209 (2022)
  24. Inactivation of the Kv2.1 channel through electromechanical coupling. Fernández-Mariño AI, Tan XF, Bae C, Huffer K, Jiang J, Swartz KJ. Nature 622 410-417 (2023)
  25. Structural modeling of the hERG potassium channel and associated drug interactions. Maly J, Emigh AM, DeMarco KR, Furutani K, Sack JT, Clancy CE, Vorobyov I, Yarov-Yarovoy V. Front Pharmacol 13 966463 (2022)
  26. Inhibition of NMDA receptors through a membrane-to-channel path. Wilcox MR, Nigam A, Glasgow NG, Narangoda C, Phillips MB, Patel DS, Mesbahi-Vasey S, Turcu AL, Vázquez S, Kurnikova MG, Johnson JW. Nat Commun 13 4114 (2022)
  27. Molecular insights into the gating mechanisms of voltage-gated calcium channel CaV2.3. Gao Y, Xu S, Cui X, Xu H, Qiu Y, Wei Y, Dong Y, Zhu B, Peng C, Liu S, Zhang XC, Sun J, Huang Z, Zhao Y. Nat Commun 14 516 (2023)
  28. Structural basis for the severe adverse interaction of sofosbuvir and amiodarone on L-type Cav channels. Yao X, Gao S, Wang J, Li Z, Huang J, Wang Y, Wang Z, Chen J, Fan X, Wang W, Jin X, Pan X, Yu Y, Lagrutta A, Yan N. Cell 185 4801-4810.e13 (2022)
  29. In silico Screening and Behavioral Validation of a Novel Peptide, LCGA-17, With Anxiolytic-Like Properties. Malyshev AV, Sukhanova IA, Zlobin AS, Gedzun VR, Pavshintsev VV, Vasileva EV, Zalevsky AO, Doronin II, Mitkin NA, Golovin AV, Lovat ML, Kovalev GI, Zolotarev YA, Kuchumov AR, Babkin GA, Luscher B. Front Neurosci 15 705590 (2021)
  30. Germline de novo variant F747S extends the phenotypic spectrum of CACNA1D Ca2+ channelopathies. Török F, Tezcan K, Filippini L, Fernández-Quintero ML, Zanetti L, Liedl KR, Drexel RS, Striessnig J, Ortner NJ. Hum Mol Genet 32 847-859 (2023)
  31. Identification of Sclareol As a Natural Neuroprotective Cav 1.3-Antagonist Using Synthetic Parkinson-Mimetic Gene Circuits and Computer-Aided Drug Discovery. Wang H, Xie M, Rizzi G, Li X, Tan K, Fussenegger M. Adv Sci (Weinh) 9 e2102855 (2022)
  32. New Insights into the Structure-Activity Relationship and Neuroprotective Profile of Benzodiazepinone Derivatives of Neurounina-1 as Modulators of the Na+/Ca2+ Exchanger Isoforms. Magli E, Fattorusso C, Persico M, Corvino A, Esposito G, Fiorino F, Luciano P, Perissutti E, Santagada V, Severino B, Tedeschi V, Pannaccione A, Pignataro G, Caliendo G, Annunziato L, Secondo A, Frecentese F. J Med Chem 64 17901-17919 (2021)
  33. Cytosolic peptides encoding CaV1 C-termini downregulate the calcium channel activity-neuritogenesis coupling. Yang Y, Yu Z, Geng J, Liu M, Liu N, Li P, Hong W, Yue S, Jiang H, Ge H, Qian F, Xiong W, Wang P, Song S, Li X, Fan Y, Liu X. Commun Biol 5 484 (2022)
  34. Divergent Ca2+/calmodulin feedback regulation of CaV1 and CaV2 voltage-gated calcium channels evolved in the common ancestor of Placozoa and Bilateria. Gauberg J, Elkhatib W, Smith CL, Singh A, Senatore A. J Biol Chem 298 101741 (2022)
  35. Dual-pocket inhibition of Nav channels by the antiepileptic drug lamotrigine. Huang J, Fan X, Jin X, Teng L, Yan N. Proc Natl Acad Sci U S A 120 e2309773120 (2023)
  36. Pore mutation N617D in the skeletal muscle DHPR blocks Ca2+ influx due to atypical high-affinity Ca2+ binding. Dayal A, Fernández-Quintero ML, Liedl KR, Grabner M. Elife 10 e63435 (2021)
  37. Cyclic Peptides as T-Type Calcium Channel Blockers: Characterization and Molecular Mapping of the Binding Site. Depuydt AS, Rihon J, Cheneval O, Vanmeert M, Schroeder CI, Craik DJ, Lescrinier E, Peigneur S, Tytgat J. ACS Pharmacol Transl Sci 4 1379-1389 (2021)
  38. Involvement of Multidrug Resistance Modulators in the Regulation of the Mitochondrial Permeability Transition Pore. Fedotcheva T, Shimanovsky N, Fedotcheva N. Membranes (Basel) 12 890 (2022)
  39. Novel Labdane Diterpenes-Based Synthetic Derivatives: Identification of a Bifunctional Vasodilator That Inhibits CaV1.2 and Stimulates KCa1.1 Channels. Carullo G, Saponara S, Ahmed A, Gorelli B, Mazzotta S, Trezza A, Gianibbi B, Campiani G, Fusi F, Aiello F. Mar Drugs 20 515 (2022)
  40. Potential binding modes of the gut bacterial metabolite, 5-hydroxyindole, to the intestinal L-type calcium channels and its impact on the microbiota in rats. Waclawiková B, Cesar Telles de Souza P, Schwalbe M, Neochoritis CG, Hoornenborg W, Nelemans SA, Marrink SJ, El Aidy S. Gut Microbes 15 2154544 (2023)
  41. Transient Ca2+ entry by plasmalogen-mediated activation of receptor potential cation channel promotes AMPK activity. Honsho M, Mawatari S, Fujino T. Front Mol Biosci 9 1008626 (2022)
  42. Unique cysteine-enriched, D2L5 and D4L6 extracellular loops in CaV3 T-type channels alter the passage and block of monovalent and divalent ions. Guan W, Stephens RF, Mourad O, Mehta A, Fux J, Spafford JD. Sci Rep 10 12404 (2020)
  43. ChanFAD: A Functional Annotation Database for Ion Channels. Castro EV, Shepherd JW, Guggenheim RS, Sengvoravong M, Hall BC, Chappell MK, Hearn JA, Caraccio ON, Bissman C, Lantow S, Buehner D, Costlow HR, Prather DM, Zonza AM, Witt M, Zahratka JA. Front Bioinform 2 835805 (2022)
  44. Computational Analysis of the Crystal and Cryo-EM Structures of P-Loop Channels with Drugs. Tikhonov DB, Zhorov BS. Int J Mol Sci 22 8143 (2021)
  45. Inhibition of N-type calcium ion channels by tricyclic antidepressants - experimental and theoretical justification for their use for neuropathic pain. Cardoso FC, Schmit M, Kuiper MJ, Lewis RJ, Tuck KL, Duggan PJ. RSC Med Chem 13 183-195 (2022)
  46. Structural basis for human Cav3.2 inhibition by selective antagonists. Huang J, Fan X, Jin X, Lyu C, Guo Q, Liu T, Chen J, Davakan A, Lory P, Yan N. Cell Res 34 440-450 (2024)
  47. Verapamil mitigates chloride and calcium bi-channelopathy in a myotonic dystrophy mouse model. Cisco LA, Sipple MT, Edwards KM, Thornton CA, Lueck JD. J Clin Invest 134 e173576 (2024)
  48. Acetaminophen treatment evokes anticontractile effects in rat aorta by blocking L-type calcium channels. Correia MC, Santos ESA, Neves BJ, Rocha ML. Pharmacol Rep 74 493-502 (2022)
  49. Calcium-gated potassium channel blockade via membrane-facing fenestrations. Fan C, Flood E, Sukomon N, Agarwal S, Allen TW, Nimigean CM. Nat Chem Biol 20 52-61 (2024)
  50. Molecular, immunological, and physiological evidences of a sphingosine-activated plasma membrane Ca2+-channel in Trypanosoma equiperdum. Pérez-Gordones MC, Ramírez-Iglesias JR, Benaim G, Mendoza M. Parasitol Res 123 166 (2024)
  51. The erythroid K-Cl cotransport inhibitor [(dihydroindenyl)oxy]acetic acid blocks erythroid Ca2+-activated K+ channel KCNN4. Rivera A, Nasburg JA, Shim H, Shmukler BE, Kitten J, Wohlgemuth JG, Dlott JS, Snyder LM, Brugnara C, Wulff H, Alper SL. Am J Physiol Cell Physiol 323 C694-C705 (2022)
  52. 4-Pyridinio-1,4-Dihydropyridines as Calcium Ion Transport Modulators: Antagonist, Agonist, and Dual Action. Domracheva I, Kanepe-Lapsa I, Vilskersts R, Bruvere I, Bisenieks E, Velena A, Turovska B, Duburs G. Oxid Med Cell Longev 2020 2075815 (2020)
  53. N-Sulfonylphenoxazines as neuronal calcium ion channel blockers. Schmit M, Hasan MM, Dongol Y, Cardoso FC, Kuiper MJ, Lewis RJ, Duggan PJ, Tuck KL. RSC Med Chem 15 2400-2412 (2024)
  54. A novel calcium channel Cavβ2 splice variant with unique properties predominates in the retina. Seitter H, Obkircher J, Grabher P, Hartl J, Zanetti L, Lux UT, Fotakis G, Fernández-Quintero ML, Kaserer T, Koschak A. J Biol Chem 299 102972 (2023)
  55. Calculations of the binding free energies of the Comprehensive in vitro Proarrhythmia Assay (CiPA) reference drugs to cardiac ion channels. Negami T, Terada T. Biophys Physicobiol 20 e200016 (2023)
  56. Editorial Editorial: Structure Related Druggability of Voltage-Gated Sodium and Calcium Ion-Channels to Treat Diseases. Gamal El-Din TM, Zimmer T, Chahine M. Front Pharmacol 13 947511 (2022)
  57. Elucidating the clandestine behavior of enantiomeric DHPs in calcium channels. Smith N, Sun H. J Gen Physiol 155 e202313481 (2023)
  58. From α1s splicing to γ1 function: A new twist in subunit modulation of the skeletal muscle L-type Ca2+ channel. Melzer W. J Gen Physiol 154 e202213182 (2022)
  59. Hesperetin Relaxes Depolarizing Contraction in Human Umbilical Vein by Inhibiting L-Type Ca2+ Channel. Tipcome K, Watanapa WB, Ruamyod K. Chin J Integr Med (2024)
  60. Honeybee CaV4 has distinct permeation, inactivation, and pharmacology from homologous NaV channels. Bertaud A, Cens T, Chavanieu A, Estaran S, Rousset M, Soussi L, Ménard C, Kadala A, Collet C, Dutertre S, Bois P, Gosselin-Badaroudine P, Thibaud JB, Roussel J, Vignes M, Chahine M, Charnet P. J Gen Physiol 156 e202313509 (2024)
  61. Probing ion binding in the selectivity filter of the Cav1.1 channel with molecular dynamics. Zhu J, Qiu H, Guo W. Biophys J 122 496-505 (2023)
  62. Unplugging lateral fenestrations of NALCN reveals a hidden drug binding site within the pore region. Schott K, Usher SG, Serra O, Carnevale V, Pless SA, Chua HC. Proc Natl Acad Sci U S A 121 e2401591121 (2024)
  63. Vietnamese Dalbergia tonkinensis: A Promising Source of Mono- and Bifunctional Vasodilators. Cuong NM, Son NT, Nhan NT, Fukuyama Y, Ahmed A, Saponara S, Trezza A, Gianibbi B, Vigni G, Spiga O, Fusi F. Molecules 27 4505 (2022)


Quick links